1. Home
  2. NEXR vs LABT Comparison

NEXR vs LABT Comparison

Compare NEXR & LABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NEXR

Nexera Technologies Ltd Ordinary Shares

N/A

Current Price

$0.47

Market Cap

4.2M

ML Signal

N/A

Logo Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

N/A

Current Price

$2.56

Market Cap

4.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NEXR
LABT
Founded
N/A
N/A
Country
Israel
United States
Employees
38
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2M
4.6M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
NEXR
LABT
Price
$0.47
$2.56
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
18.1M
276.0K
Earning Date
N/A
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$2.10
52 Week High
$1.28
$4.72

Technical Indicators

Market Signals
Indicator
NEXR
LABT
Relative Strength Index (RSI) 43.10 31.54
Support Level N/A $2.10
Resistance Level $1.28 N/A
Average True Range (ATR) 0.14 0.61
MACD -0.03 -0.10
Stochastic Oscillator 3.33 19.85

Price Performance

Historical Comparison
NEXR
LABT

About NEXR Nexera Technologies Ltd Ordinary Shares

Nexera Technologies Ltd focuses on homeland security technologies, artificial intelligence-driven solutions, and detection systems through its subsidiaries and strategic collaborations. The company collaborates with technology partners to distribute and promote new systems such as 3D imaging and electromagnetic threat detection tools, autonomous security technologies, and multi-layered security ecosystems for critical infrastructure and high-traffic venues.

About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

Share on Social Networks: